A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929. On page 1924, Efficacy end points, Conjunctival staining section, the sentence “Statistically significant reductions in the mean change from baseline in the study eye at Day 84 relative to ve...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-12-01
|
| Series: | Clinical Ophthalmology |
| Online Access: | https://www.dovepress.com/httpswwwdovepresscomcorrigendum-a-phase-iiiii-randomized-do-peer-reviewed-article-OPTH |